Vitamin and mineral deficiencies harm one-third of the world’s population, says new report

Micronutrient deficiencies are damaging the health of one-third of the world’s population and hampering the economic development of nearly every country in the Southern Hemisphere says a new report released on 21 January at the 2004 World Economic Forum in Davos, Switzerland, by UNICEF and the Micronutrient Initiative, a Canadian-based non-profit organization.

Vitamin and mineral deficiency: a global damage assessment (available at http://www.unicef.org/media/files/davos_micronutrient.pdf) concludes that current efforts to remedy micronutrient deficiencies in the world’s poorer nations are inadequate and will remain so without new and more aggressive policies. According to the report, micronutrient deficiencies have left 2 billion people living below their physical and mental potential and are having devastating consequences on children. Worst affected countries include Afghanistan, Pakistan, Cambodia, Ethiopia and most West and Central African nations.

“It’s no longer acceptable to simply identify symptoms of micronutrient deficiency in individuals and then treat them,” said UNICEF Executive Director, Carol Bellamy. “We have to protect entire populations against the devastating consequences of vitamin and mineral deficiency, especially children.”

The report summarizes results from nutritional status studies undertaken in 80 countries and identifies four target nutrients crucial to health and development both in utero and in childhood: iron, vitamin A, iodine and folate. Iron deficiency impairs mental development in young children and results in a lowering of national intelligence quotients. It also undermines adult productivity, with estimated losses of as much as 2% of gross national product while anaemia resulting from severe iron deficiency causes deaths during childbirth of an estimated 50 000 women each year.

Lack of vitamin A has left up to 40% of children less than 5 years old in the developing world with compromised immune systems, leading to the early deaths of one million young children every year.

Iodine deficiencies cause up to 20 million babies to be born with mental defects every year whilst folate deficiency results in about 200 000 severe birth defects annually such as spina bifida, encephalocele and anencephaly.

“There’s no excuse for not reaching every human being with these simple but life-saving micronutrients,” Bellamy said. “We know what needs doing, we just have to do it.”

Ian Darnton-Hill, UNICEF’s Senior Advisor for Micronutrients, said that fortification of food staples like flour, salt, sugar, cooking oil and margarine, and the distribution of vitamin supplements to at-risk groups, would be the most effective strategies.

Fortification — already used successfully for decades in the industrialized world — could have an immediate effect on micronutrient deficiencies, according to the report. For example, if wheat flour were fortified with iron and folic acid, iron deficiency could be reduced by 10% and birth defects could be lowered by a third in the neediest countries in about five years, according to Ibrahim Daibes, Communications Manager at the Micronutrient Initiative. Such fortification would cost a total of about US$ 85 million — only US$ 0.4 per person.

“Our intent is to encourage individual countries to start tackling the micronutrient problem on their own, but we recognize they will need help,” Daibes said.

The Global Alliance for Improved Nutrition, launched at a UN Special Session in May 2002, was created to pave the way. Chiefly funded by the Bill and Melinda Gates Foundation, the organization’s mission is to help governments and food producers in needy countries start their own iron, iodine and folate fortification programmes. As to vitamin A, the Micronutrient Initiative will

A food market in Alem Ktima, north-east of Addis Ababa, Ethiopia. The country is one of the worst affected by vitamin and mineral deficiencies.
work with governments and nongovernmental organizations to expand supplement distribution programmes in countries that already have them and develop new ones in those that don’t.

The report also launches an information campaign that is targeted at government agencies, media outlets and food producers in at-risk countries, highlighting the damage caused by vitamin and mineral deficiencies and emphasizing the affordability of the solutions.

Whilst fortification and vitamin distribution would have a significant impact on micronutrient deficiencies in poor countries, most public health professionals agree that these strategies alone are not enough to eradicate the problem, said Bruno de Benoist, Acting Director of WHO’s department of Nutrition for Health and Development. "Supplementation is important but it won’t solve the problem without concurrent improvement of diet, sanitation and infectious disease control,” he said.

Judith Mandelbaum-Schmid, Zurich

US and Thai Governments defend HIV/AIDS vaccine trial in Thailand

Public health officials and scientists from the US and Thailand have countered accusations by a group of HIV/AIDS researchers who questioned the scientific rationale behind a Thai and US Government-backed trial of an HIV/AIDS vaccine in Thailand.

The phase III trial is testing a vaccine combination that critics say has no "reasonable prospect of protecting anyone. In an article in Science magazine (2004;303:316), 22 HIV researchers contend that scientific evidence for the vaccine is "extremely weak," and they "doubt whether these immunogens have any prospect of stimulating immune responses anywhere near adequate for these purposes." They also argue that any new scientific knowledge that the trial might produce is not worth the US$ 119 million cost and effort.

However, in a rebuttal published in Science (2004;303:961), John McNeil and other scientific officers from the sponsoring agencies argue that the decision to proceed with the trial is "scientifically justified, morally correct and strategically important." In the same issue of Science (2004;303:954-5), Charal Trinvuthipong, Director General of the Department of Disease Control in Thailand’s Ministry of Public Health which is co-sponsoring the trial, pointed out that the critics’ argument was flawed and that "there is no such thing as wasting time or money in researching an AIDS vaccine."

In September 2003, the first of 16 000 young, heterosexual volunteers began receiving the vaccine which comprises Aventis-Pasteur’s live canarypox virus vector ALVAC combined with VaxGen’s genetically engineered HIV surface protein gp120. The Aventis-Pasteur vaccine is designed to stimulate cellular immunity by promoting the growth of cytotoxic T cells. VaxGen's gp120 vaccine aims to induce antibodies against HIV. According to the critics, phase I and II clinical trials revealed that the ALVAC vector alone was poorly immunogenic, and trials in the US and Thailand indicated that the gp120 component was “completely incapable of preventing or ameliorating HIV-1 infection.” The "prime-boost" combination vaccine was designed to strengthen cellular and humoral immunity to prevent and or control HIV-1 more than either vaccine does alone.

The critics argue that "there are no persuasive data" to support this idea. “I don’t think there’s anyone who thinks this will be protective,” said Beatrice Hahn of the University of Alabama in the US, a co-author of the critique in Science. For a phase III trial to be justifiable, there should be a "reasonable prospect" that the vaccine will benefit the study population but this prospect is lacking, argue the authors.

The article accuses the National Institutes of Health (NIH), the agency of the US Department of Health and Human Services backing the trial, of not consulting closely enough with independent experts. The authors fear that the study’s failure could erode public and political confidence in HIV/AIDS vaccines and deplete the reservoir of willing participants in future HIV/AIDS vaccine trials. “Our opinion is that the overall approval process lacked input from independent immunologists and virologists who could have judged whether the trial was scientifically meritorious,” they said.

However, McNeil and colleagues from the National Institute of Allergy and Infectious Diseases (NIAID) — the research component of NIH, and the Walter Reed Army Institute of Research in Washington which has also been involved in the project, point out that the combination vaccine was reviewed and endorsed by 11 international governmental and academic scientific, ethical and regulatory review bodies in Thailand and the US and by WHO and the Joint UN Programme on HIV/AIDS (UNAIDS). They also argue that the “prime-boost” combination did seem to increase immune responses in small phase I and phase II studies and since there is no suitable animal model, the only way to test the method further is a large human trial.

Trinvuthipong argues that the basis of the criticism is flawed “in that it uses data from efficacy trials of a single vaccine concept to predict the results of a prime-boost combination vaccine study. Only by conducting the trial will we be able to determine if the combination of two candidate vaccines will induce both cellular and humoral immunity and protect against HIV infection.”

Trinvuthipong also said that even if the trial is not successful, it will still give rise to important benefits. “Regardless of the efficacy of the results, Thailand is benefiting from conducting this trial in several areas,” he said, pointing out the importance of the experience for scientists, health workers, Thailand’s laboratory infrastructure and specimen archiving systems. “Another important benefit,” he added, “is the intensified HIV/AIDS awareness campaign around the trial, which directly benefits the local communities in Chon Buri and Rayong.

Modifications to the trial’s design are currently under way. “We certainly are looking at ways to improve the design,” said Anthony Fauci, Director of NIAID, “and we are going to be doing further immunological monitoring, so that we can get a better handle early on if [the vaccine] isn’t giving at least the immunological effect that we’re looking for,” he added. Additional scientific rationale for the trial will be published soon.

Dr Saladin Osmanov, from the WHO–UNAIDS Vaccine Initiative said that “no one can guarantee that this trial will result in an efficacious vaccine, but what we can guarantee is that if we do not conduct clinical trials, we will never have an AIDS vaccine.”

Bruce Agnew, Bethesda, USA